We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Diabetes

Journal Scan / Research · July 29, 2020

Impact of Albiglutide on Glycemic Control and Reducing Prandial Insulin Use in Type 2 Diabetes

Diabetes Care

 

Additional Info

Disclosure statements are available on the authors' profiles:

Diabetes Care
Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial
Diabetes Care 2020 Jul 21;[EPub Ahead of Print], J Rosenstock, A Nino, J Soffer, L Erskine, A Acusta, J Dole, MC Carr, J Mallory, P Home

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading